We only have this paper's title and publication details.
Read it at the sourceClinical study reveals baseline tumor size independently predicts overall survival in melanoma patients receiving pembrolizumab, highlighting tumor burden as an essential prognostic biomarker.
.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: